Produktname:4-bromopyridine hydrochloride
IUPAC Name:4-bromopyridine hydrochloride
- CAS:19524-06-2
- Molekulare Formel:C5H5BrClN
- Reinheit:95%+
- Katalognummer:CM104110
- Molekulargewicht:194.46
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:19524-06-2
- Molekulare Formel:C5H5BrClN
- Schmelzpunkt:-
- SMILES-Code:Cl.BrC1=CC=NC=C1
- Dichte:
- Katalognummer:CM104110
- Molekulargewicht:194.46
- Siedepunkt:
- Mdl-Nr.:MFCD00012828
- Lagerung:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Tradipitant
- Vanda announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years and to be accepted for review by the FDA for gastroparesis in over 30 years. Tradipitant is an NK-1R antagonist. It works by blocking substance P, a small signaling molecule. Tradipitant can affect gastric peristalsis and directly affect neurotransmission in the brain area responsible for nausea and vomiting, thus playing a role in the treatment of symptoms of gastroparesis. This NDA is mainly based on the results of the Phase II VP-VLY-686-2301 study and the Phase III VP-VLY-686-3301 study.